The head of Africa's public health agency has said the core tool for controlling an Ebola outbreak is no longer working in eastern Congo. Africa CDC Director-General Jean Kaseya, speaking during his second visit to Bunia near the outbreak's epicenter, said flatly that contact tracing is not working and that he does not like the outbreak's trajectory.
Kaseya said most new cases are arriving not through traced contacts but through community spread. News accounts of his remarks have placed that share between roughly 60 and 80 percent, and the figure should be read as an estimate rather than a fixed statistic. The confirmed toll stands at 3,802 cases and 1,707 deaths since the outbreak was declared on May 15, according to the latest government update.
That gap is the news, more than the death count itself. When most new cases come from known contacts, officials can see the outbreak's shape and estimate where it is heading. When most cases appear outside the traced network, they are measuring the epidemic after the fact. Kaseya said it is not clear when the outbreak will reach its peak, and the patient identified as the origin of the outbreak has still not been found.
The Strain Involved Has No Approved Vaccine or Treatment
This outbreak is caused by Bundibugyo virus, a rarer member of the Ebola family than the Zaire strain that most global stockpiles were built to counter. There is no licensed vaccine and no approved specific treatment for Bundibugyo virus disease, though WHO notes that early supportive care is lifesaving.
That gap changes the arithmetic of the response. In the 2018 to 2020 Kivu epidemic, ring vaccination around confirmed contacts was a central control measure. Here, ring vaccination is not available as a licensed intervention, which places a heavier burden on exactly the tool Kaseya says has failed.
Two clinical trials of post-exposure prophylaxis drugs are underway in Ituri province, and two separate vaccine trials are running in the United Kingdom and Canada. MedicalDaily previously reported on Africa CDC's move to test Merck's licensed Ebola vaccine against Bundibugyo virus, an effort to determine whether existing products offer any cross protection. Vasee Moorthy, acting head of WHO's research and development blueprint program, told reporters in Geneva that trials had started faster than in previous outbreaks and that preclinical data looked promising, while cautioning that only clinical trials will show whether the products work.
Two Official Pictures of Tracing Sit Side by Side
The surveillance situation is not uniformly bleak, and readers deserve both numbers. Al Jazeera reported, citing WHO data, that more than 17,000 contacts are being monitored, with about 80 percent followed up each day.
Those figures are not contradictory. Contact tracing can be operating at scale and still be failing in the sense Kaseya described, because the test is not how many listed contacts get a daily check. The test is whether new cases turn out to be people already on the list. When most are not, the tracing net is being built around a transmission chain that has already moved past it.
Africa CDC has attributed the difficulty to delays in contact tracing, problems reaching affected areas, community mistrust and violence from armed groups and some residents. WHO says more than 100 health workers have been infected since the outbreak began, and the response also faces a significant funding shortfall. Nearly 90 percent of cases are concentrated in Ituri province, but cases have been confirmed in five other provinces, including Kisangani, one of the country's largest cities.
Spread to Cities Is the Development US Officials Are Watching
The reason this matters outside central Africa runs through urban transmission and air travel. An outbreak confined to remote districts is a containment problem. An outbreak seeded into large cities becomes an export risk, because cities have airports.
That risk is not hypothetical. According to the European Centre for Disease Prevention and Control, an imported case was reported in France in late June, and US CDC reported in July that a US citizen working for a humanitarian organization in DRC had tested positive and was medically evacuated to Germany. Uganda recorded imported cases linked to travel from DRC earlier in the outbreak and declared itself Ebola-free in mid June after its last patient was discharged.
WHO declared the outbreak a Public Health Emergency of International Concern on May 17, and CDC has maintained entry restrictions and airport screening for travelers arriving from DRC, Uganda and South Sudan. The CDC situation summary notes the border order first took effect in May and has been continued on a rolling 30-day basis, most recently in an order issued July 13. MedicalDaily previously covered the renewal of those US entry measures.
For US households, the practical risk remains low, and no cases of Bundibugyo virus disease linked to this outbreak have been acquired in the United States. The people with an immediate stake are travelers to the region, health workers deploying there, and families with relatives in affected provinces. Anyone who has been in the outbreak zone within 21 days and develops fever, severe headache, muscle pain, vomiting, or unexplained bleeding should call ahead to a health facility rather than walking into a waiting room, so staff can prepare for isolation.
The Next Signals to Watch
WHO Director-General Tedros Adhanom Ghebreyesus traveled to Kinshasa and was expected to visit Bunia, a visit that typically precedes announcements on funding, staffing or trial expansion. Updated case and death figures come from the DRC Ministry of Health, with WHO situation reports and Africa CDC briefings providing weekly context.
The specific things to watch are whether the share of cases arising from known contacts rises, which would indicate tracing is regaining ground, whether confirmed cases appear in additional urban centers, and whether the ongoing therapeutic and vaccine trials report interim results.
Several things remain unconfirmed. The index case has not been identified. There is no reliable projection of when the outbreak will peak. Whether licensed Ebola vaccines confer meaningful protection against Bundibugyo virus has not been established. Reported case and death totals are also widely understood to undercount an epidemic spreading in areas that responders cannot reliably reach.
The most reasonable position for readers is neither alarm nor dismissal. This is the second largest Ebola outbreak ever recorded and the fastest growing, driven by a strain with no licensed countermeasures, and the officials responding to it are saying publicly that they cannot currently see where it is going.
Frequently Asked Questions
How many people have died? DRC government figures put the toll at 1,707 deaths among 3,802 confirmed cases as of Aug. 4.
Why does failed contact tracing matter so much? Without it, officials cannot measure the outbreak's true size or predict a peak, and cases are found only after transmission has already occurred.
Is there a vaccine? Not for Bundibugyo virus. Licensed Ebola vaccines target the Zaire strain. Trials are underway to test whether they offer cross-protection.
Is there any risk to people in the United States? No linked cases have been acquired in the US. Risk is concentrated among travelers to the region and health workers.
Are there travel restrictions? CDC has maintained entry and screening measures for travelers arriving from DRC, Uganda, and South Sudan through successive 30-day renewals.
What are the symptoms? Fever, severe headache, muscle pain, weakness, vomiting, diarrhea, abdominal pain, and in some cases unexplained bleeding, typically appearing within 21 days of exposure.
Who should seek care? Anyone with those symptoms within 21 days of being in the outbreak zone should call a health facility in advance rather than arriving unannounced.
